2026-08-09 · 2026-08 / week-2
My Size's $10 Million ELOC Is Not $10 Million of Cash
My Size's $10 Million ELOC Is Not $10 Million of Cash
Summary: My Size (Nasdaq: MYSZ) has registered a potential $10 million equity line, but the current filing bridge shows a price-gated and capped funding path beside a weak latest balance sheet. The short research question is whether the market is pricing the headline facility as clean runway before the first purchase notice, the first cash receipt, or a new share-count filing exists.
The August 7 Form S-1 registers up to 26.019 million shares against 5.395 million common shares outstanding. That is potential supply, not immediate float. The same documents state that the ELOC is subject to a 1.024597 million share exchange cap unless stockholder approval or a price condition removes it, while the company has already issued 269,229 free commitment shares and may issue up to 750,000 true-up shares. The short is conditional research, not personalized financial advice.
Research timestamp: 2026-08-09 14:41 Asia/Ho_Chi_Minh, UTC+07:00. Market data is timestamped separately below.
Evidence labels: SEC filings and filed financial statements are facts. The claim that the market may be over-crediting the ELOC as usable cash, the scenario levels, and the probabilities are judgmental inferences. Same-session spread, depth, venue, borrow, locate, short interest, options, dealer-flow, fund-flow, and exit liquidity were not verified.
Why This Is the Best Opportunity Right Now
This run was limited to U.S. short opportunities. I scanned articles/2026-08/week-2/ and the repository for ticker, company, financing, ELOC, resale, warrant, and cash-conversion duplicates. MYSZ has no prior primary article in the reviewed repository. SILO appears as a secondary candidate in a recent GCTK article, so it was not selected for a new publication.
The creative EDGAR search set used combinations of "equity line" "going concern", "pre-funded warrants" "registered for resale", "registration statement" "true-up commitment shares", and "registered direct offering" "cash and equivalents". This produced a fresh set of filing-led U.S. short candidates rather than a generic earnings list.
| Rank | Candidate | Current reference | Fresh evidence | Catalyst and payoff tension | Why it ranks here |
|---|---|---|---|---|---|
| 1 | MYSZ conditional short Watchlist | $0.39, provider snapshot at 2026-08-08 00:15 UTC | August 5 8-K, August 7 S-1, May 14 10-Q | A $10 million ELOC headline versus a $0.3706 price condition, a 19.99% exchange cap, free commitment shares, and cash that covered less than one recent quarter of operating burn | Best combination of fresh primary evidence, financing urgency, a dated registration gate, and a measurable gap between headline capacity and accessible cash |
| 2 | SILO short Watchlist | $3.735, provider snapshot at 2026-08-08 00:15 UTC | August 6 424B3 and May 14 10-Q | Registered resale of 1.906 million shares against 1.253 million common shares, but only 495,965 shares are pre-funded and the company reported more than twelve months of cash and liquid investments | The supply ratio is large, but the out-of-the-money warrants and stronger liquidity reduce near-term funding pressure; the mechanism was also already discussed as a secondary candidate |
| 3 | ATOS short Watchlist | $2.36, provider snapshot at 2026-08-08 00:15 UTC | August 7 Q2 release and registered-direct financing disclosure | 1.364 million common shares plus two warrant tranches raised $4.5 million upfront, with up to $12 million of additional cash exercise, while clinical optionality remains active | Fresh financing evidence is useful, but the stock is already below the approximate $3.30 upfront gross-per-common-share arithmetic and the new cash plus clinical path create a stronger squeeze case |
MYSZ is not the strongest company-level short in the abstract. It is the cleanest current U.S. research question: can a microcap with a March going-concern warning convert a conditional equity line into enough unrestricted cash before the denominator and free commitment shares pressure the tape? SILO has more visible registered supply but less urgency. ATOS has a more credible cash and clinical counterargument.
Why This Can Jump Or Dump More Than 5% Soon
Fact: The market-data provider reports MYSZ at $0.39, up 4.24% from the prior close, with an open of $0.38, a reported low of $0.3701, volume of 26,252 shares, and provider market capitalization of approximately $1.87 million. The latest trade time is 2026-08-08 00:15 UTC, or 2026-08-07 20:15 ET. This is a reference snapshot, not a verified executable quote.
Fact: The August 7 S-1 states that the August 5 closing price was $0.3857 and the initial commitment-share reference price was $0.3706. The current reference is only about 5.2% above that price gate.
Inference: A filing showing effectiveness, a true-up trigger, a first Put Notice, or a post-financing share count can move a low-float stock by more than 5% because the market is close to the contractual threshold. The same stock can squeeze if the S-1 remains inactive, the company does not draw, a strategic or non-dilutive source appears, or operating traction makes the ELOC irrelevant.
Unknown: Volume does not identify short positioning. No current borrow, locate, short-interest, options, dealer-flow, or fund-flow evidence was verified. The price can move sharply without validating either the supply thesis or the short expression.
What Should Surprise the Reader
The surprising detail is not the 26 million registered shares. It is that the ELOC's nominal size and its current access conditions describe different economic objects.
Fact: The August 5 8-K gives MYSZ the right, not the obligation, to direct Square Gate Capital to purchase up to $10 million of common stock over 36 months, subject to the agreement's conditions and limits. The company decides whether to submit a Put Notice.
Fact: The August 7 S-1 registers 25 million ELOC shares, 269,229 initial commitment shares, and up to 750,000 true-up commitment shares. MYSZ says it may receive up to $10 million from ELOC sales it elects to make, but the actual amount cannot be determined. It receives no proceeds from the selling stockholder's resale of shares.
Fact: The ELOC has a 19.99% exchange cap, equal to 1.024597 million shares under the agreement's stated denominator, unless stockholder approval or the average-price condition applies. Each Put Notice is also subject to a 4.99% beneficial-ownership limitation. The regular purchase price is 96.5% of the lowest daily VWAP during the valuation period, while the intraday formula uses the lowest traded price during its valuation period.
Inference: At the current reference, the uncapped headline is not a near-term $10 million cash bridge. A stress calculation values the 1.024597 million-share exchange cap at about $0.40 million at $0.39, before the 3.5% regular-put discount and other constraints. That is about 19% of the latest quarter's $2.069 million operating cash use. This is not a forecast of how many shares will be sold.
The Setup
My Size sells measurement and e-commerce-related products and is attempting to commercialize additional software and technology assets. The short thesis is not that the products are worthless. It is that the financing documents do not yet prove the cash runway implied by the headline facility.
The August 5 Form 8-K supplies the Equity Purchase Agreement and registration-rights terms. The August 7 Form S-1 supplies the registered-share and selling-stockholder bridge. The May 14 Form 10-Q supplies the latest filed cash, burn, and going-concern evidence.
| Latest filed Q1 2026 measure | Result | Interpretation |
|---|---|---|
| Revenue | $2.394M, versus $1.479M in Q1 2025 | Revenue improved, so this is not a pure zero-revenue story |
| Operating loss | $1.406M | Revenue growth had not produced operating breakeven |
| Net loss | $1.476M | Losses continued while the funding need remained active |
| Cash and cash equivalents at March 31 | $0.654M | Latest filed unrestricted cash was small relative to burn |
| Restricted cash at March 31 | $0.256M | Not the same as unrestricted operating cash |
| Net cash used in operating activities in Q1 | $2.069M | About 3.2 times period-end unrestricted cash |
| Total current liabilities | $3.666M | Current claims exceeded cash and restricted cash combined |
| Accumulated deficit | $71.204M | Long-running funding dependence remains a filed fact |
| Going-concern language | Existing cash expected to fund operations for less than 12 months | Management identified substantial doubt and listed financing among mitigation plans |
The 10-Q is dated March 31 and was filed May 14, so it is not a current cash statement. That age is itself a risk to the short thesis. The next cash and share-count filing is the adjudicator.
The Market Price
| Field | Observation |
|---|---|
| Latest provider reference | $0.39 |
| Latest trade timestamp | 2026-08-08 00:15 UTC, or 2026-08-07 20:15 ET |
| Provider change and open | +4.24% from prior close; open $0.38 |
| Provider reported low and volume | $0.3701 low; 26,252 shares |
| Provider screening market capitalization | Approximately $1.868M, not reconciled to the latest filed denominator |
| Filed common shares | 5.394778M as of August 6, 2026 |
| Filing-based price-only equity value at $0.39 | Approximately $2.104M |
| Headline ELOC capacity as a percentage of filing-based value | Approximately 475%, but not immediate cash or float |
| Market-data status | Reference only. Same-session spread, depth, venue, borrow, and exit liquidity were not verified |
The provider market capitalization is about 11% below the filing-based $0.39 times 5.394778 million calculation. That conflict is not a detail to smooth over. The filing-based figure is used only for a labeled stress comparison, while the signal preserves the provider quote as reference_price and leaves executable entry.price null.
The Positioning
Observed: Square Gate is the named investor and selling stockholder in the ELOC documents. MYSZ issued 269,229 initial commitment shares for a stated $100,000 commitment fee and may owe up to 750,000 true-up shares if the effectiveness-date reference price falls below $0.3706. The commitment shares are earned as of execution and may be resold when the registration becomes effective.
Plausible but unverified: The full registered package of 26.019 million shares is more than 4.8 times the 5.395 million filed common denominator. The more relevant current stress is the 1.024597 million exchange cap plus the 1.019229 million maximum commitment-share package. Those are potential supply states, not shares sold.
Missing: I found no verified first Put Notice, settled ELOC purchase, actual ELOC share issuance, exercise notice, or resale that proves current market supply. The investor also covenanted not to cause or engage in short sales or hedging transactions in MYSZ shares. Positioning is therefore capped at 3/5. A registration statement is not a short-interest report.
The ELOC and Denominator Bridge
| Instrument or state | Filed amount | What it means | What it does not prove |
|---|---|---|---|
| Common shares outstanding | 5.394778M | Latest filed denominator as of August 6 | Does not include future ELOC or true-up issuance |
| ELOC headline commitment | Up to $10.0M over 36 months | Potential issuer funding if MYSZ elects to sell and conditions are met | Does not equal cash received or a current float increase |
| Registered ELOC shares | Up to 25.0M | Resale registration capacity for shares that may be issued | Does not prove issuance, exercise, or resale |
| Exchange cap | 1.024597M shares | Contractual cap absent approval or the average-price exception | Does not guarantee that the cap can be sold or that cash arrives |
| Per-Put ownership limit | 4.99% of then outstanding | Limits a particular purchase notice | Does not create a floor or prove a notice was delivered |
| Initial commitment shares | 269,229 | Free shares issued for the commitment fee | Does not prove the investor has sold them |
| True-up commitment shares | Up to 750,000 | Additional free shares if the effectiveness-date reference falls below $0.3706 | Not currently issuable based on the August 5 $0.3857 close, subject to the later reference test |
| Current cap value stress | About $0.400M at $0.39 | Illustrative value of the exchange cap at the reference price | Ignores discount, volume, price impact, and whether a sale occurs |
| Q1 operating cash use | $2.069M | Latest reported quarterly operating cash drain | Does not forecast the next quarter or current cash |
The filing states that the exchange cap does not apply if stockholders approve issuance above it or if the average price of applicable sales equals or exceeds $0.3706. If the average price falls below $0.3706, MYSZ may be limited to the 1.024597 million shares without approval. Because the current reference is only modestly above the threshold and the contract includes free commitment shares in its average-price mechanics, access is a legal and price path, not a simple capacity ratio.
The Catalyst Path
- Registration effectiveness: The 8-K required MYSZ to submit the S-1 by the 30th calendar day after the registration-rights agreement. The August 7 filing is evidence of submission, not evidence that the SEC has declared it effective. The commitment shares cannot be treated as freely resellable before the relevant registration or Rule 144 condition.
- True-up test: If the effectiveness-date reference price is below $0.3706, up to 750,000 additional free commitment shares may be issued. The August 5 closing price was above the threshold, so this is a conditional catalyst rather than current dilution.
- First Put Notice or settlement: The first notice, VWAP, share amount, cash received, and post-settlement denominator are more informative than the $10 million headline. The regular formula carries a 3.5% discount to the lowest daily VWAP.
- Next cash and share-count filing: The next 10-Q or 8-K should show whether the line was used, whether cash arrived, whether the denominator expanded, and whether the business still needs more funding. No exact next filing date was confirmed in the reviewed sources.
- Operating invalidation: Revenue growth, unrestricted cash above at least one quarter of recent operating use, and a credible non-dilutive or strategic capital source would make the ELOC supply thesis less relevant.
The cheapest disconfirming sequence is S-1 effectiveness, true-up disclosure, first settled ELOC purchase, post-financing cash and share count, then the next operating-cash-flow filing. A registration clock is not resale evidence.
The Gap
The market can see a $10 million funding line. The filing shows a company with $0.654 million of March unrestricted cash, $2.069 million of Q1 operating cash use, a price gate near the current quote, and an exchange cap that can make near-term access materially smaller than the headline.
The mispricing is not “ELOC equals dilution.” It is narrower: the tape may be assigning value to a clean source of runway before anyone has shown the first Put Notice, the first settled purchase, the first cash receipt, or an effective resale registration. At the same time, the market may not be pricing how quickly free commitment shares and a sub-threshold effectiveness price could create supply in a low-float name.
The Payoff Map
The map uses the $0.39 provider reference and a one-to-three-month catalyst horizon, subject to the next filing sequence. These are scenario levels for a conditional research thesis, not instructions to trade.
Price Target and Probability Map
| Scenario | Probability | Target / level | Price-only short payoff from $0.39 reference | Conditions required | Evidence quality |
|---|---|---|---|---|---|
| Top case, short works | 30% | $0.10 | +74.4% gross | S-1 becomes effective, true-up or ELOC supply appears, cash remains inadequate, and the next filing shows a larger denominator without operating rescue | Medium. Capital mechanics are filed; timing and resale are not |
| Base case | 50% | $0.25 | +35.9% gross | Registration and funding uncertainty remain, revenue growth does not cover burn, and the market discounts the line as conditional rather than as cash | Medium. Q1 cash and burn are filed; Q2 is pending |
| Bottom case, squeeze or invalidation | 20% | $0.60 | -53.8% gross | No ELOC draw, no true-up, non-dilutive or strategic funding arrives, revenue improves, or a low-float rally overwhelms the financing thesis | Medium-low. The squeeze path is plausible but not yet evidenced |
| Review condition | n/a | Review above $0.60 with fundamental confirmation | Not a price-only stop | Sustained price strength plus cash improvement, revenue conversion, no new funding need, or a clean no-issuance filing | High for the rule, low for the future outcome |
Probability check: 30% + 50% + 20% = 100%.
Probability-weighted expected price: (0.30 x $0.10) + (0.50 x $0.25) + (0.20 x $0.60) = $0.275, or approximately $0.28. Against the $0.39 reference, that is a 29.5% price-only gross short return before borrow fees, locate costs, financing, taxes, slippage, and gap risk. Executable EV cannot be computed because live borrow, locate, spread, depth, venue, and exit-liquidity data are unverified.
The probabilities are judgmental scenario weights, not a statistical forecast. They express the evidence boundary: the capital gap is documented, but actual supply and tradeability are not.
What Could Go Wrong
The strongest counterargument is that MYSZ does not need to draw the ELOC. The latest quarter showed revenue growth, the investor cannot short or hedge the shares under the agreement, and a strategic investor, product sale, non-dilutive grant, or operating improvement could make the registration irrelevant. A stock at $0.39 can also rally sharply because its filed denominator is small, even if no fundamental value has changed.
| Risk | Why it matters | Control |
|---|---|---|
| ELOC is never drawn | The headline capacity can remain unused while the company finds another funding source | Require a Put Notice, settlement, and cash receipt before calling supply current |
| Non-dilutive or strategic funding | Cash can extend runway and remove the near-term dilution incentive | Reconcile the new cash, restrictions, and post-funding share count |
| Revenue improvement | The Q1 revenue increase can become a real operating inflection | Require the next revenue, margin, and operating-cash-flow filing |
| Price-gate exception | Average price at or above $0.3706 or stockholder approval can expand access above the exchange cap | Track the actual average price, approval, and issued shares, not the registration maximum |
| Registered shares remain unsold | Potential supply can fail to affect the tape | Do not upgrade positioning without actual resale or issuance evidence |
| Microcap squeeze | A small denominator and low reported volume can overpower the capital thesis | No short without locate, borrow, stable spread, depth, and exit liquidity; do not short an intraday low |
| Stale financials | March cash and burn may not describe August liquidity | Use the next cash and share-count filing as the adjudicator |
| Provider market-cap conflict | Vendor fields can misstate the equity value | Use filed shares times reference price for stress math and disclose the conflict |
Risk Audit
The core failure mode is timing. A registration may remain pending while the company finds cash, and the stock may rally before a short can be located or covered. The second failure mode is arithmetic overreach. The 26.019 million registered shares are not current float, the $10 million ELOC is not current cash, and the 1.024597 million exchange cap is not a forecast of shares sold.
The short thesis is therefore conditional twice: first on a filing sequence that makes the financing relevant, and second on a verified market-structure path that makes the expression executable. Missing either path is a reason to remain a Watchlist, not to force a trade.
What Would Prove This Wrong
The thesis is wrong if MYSZ obtains unrestricted or strategically committed capital sufficient to cover the near-term operating gap without meaningful equity issuance, if the next filing shows revenue and cash conversion improving, or if the S-1 becomes ineffective or irrelevant without a new financing need.
It is also wrong if the stock sustains a move above $0.60 with a documented operating or funding improvement, the company does not issue true-up or ELOC shares, and the next denominator filing remains stable. A price-only bounce is not enough to invalidate the capital thesis, but a price bounce with cash and operating confirmation is.
Best Trade Strategy
- Direction: Conditional short Watchlist only.
- Preferred instrument: MYSZ common stock on Nasdaq, subject to verified borrow and market structure.
- Common-stock stance: No executable entry. The $0.39 quote is a provider reference.
entry.priceremainsnull. - Execution gate:
execution.can_execute=false. No verified locate, borrow, acceptable recall terms, same-session spread, depth, venue, volume quality, or exit liquidity means no trade. - Options stance: No options. The live chain, open interest, implied volatility, dealer positioning, and liquidity were not verified.
- Take-profit map: Review the $0.25 base and $0.10 top levels only after the registration, cash, and share-count sequence confirms the thesis.
- Stop or invalidation: Review above $0.60 when accompanied by cash improvement, revenue conversion, non-dilutive funding, or a stable denominator. A price-only stop is not a substitute for the thesis invalidation.
- Timeline: Immediate reference after the August 7 S-1 filing; catalyst path runs through effectiveness, any true-up, the first Put Notice or settlement, and the next quarterly filing. No exact next filing date was verified.
- Execution risks: Opening gap, borrow recall, punitive borrow fee, short-sale restrictions, halt, wide spread, shallow depth, stale quote, registration delay, investor retention, strategic funding, and low-float squeeze.
- Do-not-trade conditions: No locate; no borrow; unstable or wide spread; weak exit liquidity; stale or after-hours-only quote; halt or disorderly tape; fresh positive operating filing; unverified option chain; or any attempt to use the 26.019 million registered shares as immediate float.
- Monitoring checklist: S-1 effectiveness; true-up share notice; first Put Notice; purchase price and VWAP; shares settled; cash received; post-financing common count; Q2 revenue and margin; operating cash flow; unrestricted cash; strategic or non-dilutive financing; actual resale; current short interest; borrow fee and recall terms; options; spread; depth; venue; and exit liquidity.
Bottom Line
MYSZ's ELOC is real, but the headline is not cash. The latest filed balance sheet showed $0.654 million of unrestricted cash against $2.069 million of Q1 operating cash use. The registration shows 26.019 million potential shares, while the agreement's exchange cap and price condition make current access much narrower and more conditional than the headline suggests.
The short edge is price-only and conditional. The financing evidence is fresh and the catalyst path is concrete, but actual issuance, resale, borrow, and same-session liquidity remain unverified. The correct publication stance is a 3/5 conditional common-stock short Watchlist with fail-closed execution, not an executable trade.
The cheapest next test is the sequence of S-1 effectiveness, true-up disclosure, first settled ELOC purchase, post-financing cash and share count, and the next operating-cash-flow filing. Until that sequence and a verified locate exist, the market reference is research context only.
Research Quality Scorecard (Canonical Rubric)
| Criterion | Score | Rationale |
|---|---|---|
| Market disagreement | 5 | The market can read $10 million of ELOC capacity as clean runway while the contract makes access conditional and capped |
| Evidence base | 5 | The thesis uses the August 5 8-K, August 7 S-1, May 14 10-Q, and timestamped market data |
| Positioning and flows | 3 | Registered claims and the investor are visible, but actual resale, borrow, short-interest, and flow data are missing |
| Catalyst path | 5 | Effectiveness, true-up, first Put Notice, settlement, and the next cash/share-count filing are concrete adjudicators |
| Payoff architecture | 4 | Price-only asymmetry is meaningful, but microcap gap and borrow risk can erase it |
| Invalidation discipline | 5 | Cash improvement, revenue conversion, no issuance, and price confirmation are kept separate |
| Differentiated insight | 5 | The analysis separates headline capacity, exchange-cap access, free shares, cash, and actual float |
| Client value | 4 | The monitoring sequence is useful even if no trade is taken |
| Total | 36 / 40 | Publish as a conditional Watchlist short, not an executable trade |
The section 17 pre-publication gate is answered yes for a specific mispricing, primary evidence, labeled positioning uncertainty, a closing catalyst, an honest downside case, the strongest counterargument, usefulness without a trade, sourced factual claims, non-hype language, opportunity ranking, greater-than-5% move logic, surprise factor, probability sum, Markdown tables, the canonical rubric, an inline illustration prompt, Best Trade Strategy, technical-signal independence, and explicit missing-data notes. The user explicitly scoped this run to U.S. markets, so the non-U.S. geographic-lane requirement is not applicable.
Sources and Data Audit
| Source | Tier | Date / timestamp | Use |
|---|---|---|---|
| My Size August 5 Form 8-K | Primary SEC filing | August 5, 2026 | ELOC amount, 36-month term, exchange cap, price condition, commitment shares, Put Notice terms, and investor restrictions |
| My Size August 7 Form S-1 | Primary SEC filing | August 7, 2026 | 26.019 million registered shares, 5.394778 million filed common shares, proceeds caveat, and true-up mechanics |
| My Size Q1 2026 Form 10-Q | Primary SEC filing | Filed May 14, 2026 | Cash, restricted cash, current liabilities, operating cash use, revenue, losses, and going-concern language |
| MYSZ quote reference | Market-data reference | 2026-08-08 00:15 UTC | $0.39 reference, change, open, low, volume, and provider market-cap field; not an executable quote |
| Silo Pharma August 6 Form 424B3 | Primary SEC filing | August 6, 2026 | Ranked alternative: registered shares, pre-funded warrants, warrant strikes, and conditional issuer proceeds |
| Silo Pharma Q1 2026 Form 10-Q | Primary SEC filing | Filed May 14, 2026 | Ranked alternative: cash, liquid investments, operating cash use, and going-concern assessment |
| SILO quote reference | Market-data reference | 2026-08-08 00:15 UTC | $3.735 reference, move, volume, and screening fields |
| Atossa Q2 2026 release, Exhibit 99.1 | Primary SEC filing | August 7, 2026 | Ranked alternative: registered direct shares, warrants, $4.5 million upfront proceeds, and clinical cash use |
| ATOS quote reference | Market-data reference | 2026-08-08 00:15 UTC | $2.36 reference, move, volume, and screening fields |
AI Illustration Prompt
Create a realistic, high-value, high-end elite editorial cover image for The Mispricing Desk about a microcap equity line whose headline capacity is much larger than its immediately accessible cash. Stage the scene inside a dark institutional financing room. On the left, place a luminous but restrained steel document engraved MYSZ ELOC $10.0M / 36 MONTHS; connect it to a narrow valve marked 19.99% EXCHANGE CAP and a price gauge set at $0.3706. On the right, show a small transparent cash reservoir labeled Q1 CASH $0.654M beside a larger red ledger labeled Q1 OCF USE $2.069M. Behind the desk, a tall stack of registration certificates reads 26.019M REGISTERED, while a much smaller illuminated denominator plate reads 5.395M COMMON; make the certificates visibly potential claims, not cash. Add a subtle free-share packet marked 269,229 INITIAL / 750,000 TRUE-UP and a quiet market panel showing $0.39 REFERENCE / ENTRY NULL. The mood should be forensic, skeptical, expensive, and unresolved, with graphite, paper white, steel blue, muted amber, and one controlled red accent. Avoid rockets, memes, casino imagery, generic candlestick charts, cartoon money, and biotech clichés. Include a subtle but legible watermark reading The Mispricing Desk.